Evinacumab placebo

Phase 2

Evinacumab placebo is one of 3 therapeutic programs targeting Diabetic Kidney Disease (DKD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetic Kidney Disease (DKD)Recruiting

Diabetic Kidney Disease (DKD)Phase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Diabetic Kidney Disease (DKD)

#DrugCompanyPhaseTrials

EVKEEZA

Regeneron

Phase 2

1 2

ALN-ANG3

Regeneron

Phase 2

1 3

Evinacumab placebo

Regeneron

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Diabetic Kidney Disease (DKD)

NCT07271186

Clinical

Trials by Indication[1]

Diabetic Kidney Disease (DKD)1 trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT07271186·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Evinacumab placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Evinacumab placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Regeneron

Evinacumab placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Diabetic Kidney Disease (DKD)1 trial

References

Drug Info

Quick Facts

Related News